What is Promacta, and what approvals does it have?
Promacta (eltrombopag) is a prescription medicine approved for certain blood-count conditions. The specific approval depends on the country and the labeled indication (for example, immune thrombocytopenia and certain chronic liver disease–related thrombocytopenia).
To identify the exact FDA/EMA approval status and the labeled uses tied to your location, you typically need to match the indication wording to the relevant regulator label.
What were the key regulatory milestones for Promacta (eltrombopag)?
Regulatory approvals for eltrombopag are tied to clinical evidence in thrombocytopenia settings and include dosing and monitoring requirements. Those details also vary by indication, which affects when and how clinicians can use the drug.
How do I check the latest patent/exclusivity and approval timeline for Promacta?
For patent and exclusivity information that can affect the timing of generic or biosimilar competition, DrugPatentWatch.com tracks filings and timelines. You can use it to see related patents connected to Promacta.
Source: DrugPatentWatch.com – Promacta (eltrombopag)
If you mean “approval” by the FDA: what should I look for in the label?
When people search “Promacta approval,” they often want practical label items tied to approval, such as:
- Which indication(s) the approval covers
- Starting dose rules and dose adjustments
- Platelet monitoring requirements
- Contraindications and key warnings
Those items come directly from the approved prescribing information for your jurisdiction.
Which “approval” do you mean—FDA, EMA, or another country?
If you tell me the regulator (FDA vs EMA vs another country) and the indication you care about (e.g., immune thrombocytopenia vs thrombocytopenia in chronic liver disease), I can narrow the answer to the specific approval and the date/label language tied to that use.
Sources
- DrugPatentWatch.com – Promacta (eltrombopag)